3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 2/3
1
Status
Recruiting
2
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
4
Sponsor
Cancer Type
Plasma cell
2
Lymphoid
2
Tumor-Agnostic
1
Thoracic
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Melanoma
23
Multiple Myeloma
9
Colorectal Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Glioma
8
Thyroid Neoplasms
7
Neoplasm Metastasis
7
Hematologic Neoplasms
6
Thyroid Carcinoma, Anaplastic
5
Lymphoma
5
Thyroid Cancer, Papillary
4
Pancreatic Neoplasms
4
Neurofibromatosis 1
4
Neoplasms
4
Lung Neoplasms
3
Brain Neoplasms
3
Astrocytoma
3
Adenocarcinoma, Follicular
3
Skin Neoplasms
2
Recurrence
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neurofibroma, Plexiform
2
Leukemia, Myelomonocytic, Juvenile
2
Histiocytosis, Langerhans-Cell
2
Glioblastoma
2
Colonic Neoplasms
2
Advanced Solid Tumors
2
Uveal Melanoma
1
Interventions
pembrolizumab
90
Blood Specimen Collection
41
Cyclophosphamide
37
Bevacizumab
36
Nivolumab
35
Standard of Care
32
Carboplatin
31
Surveys and Questionnaires
29
Paclitaxel
27
atezolizumab
25
Exercise
25
Pemetrexed
24
Gemcitabine
23
Cisplatin
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Docetaxel
19
Oxaliplatin
18
Rituximab
16
Irinotecan
16
Cetuximab
16
dostarlimab
15
Drug Therapy
15
Doxorubicin
15
Ipilimumab
14
Biopsy
14
130-nm albumin-bound paclitaxel
14
fludarabine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Neoplasms
×
trametinib
×
1 year
×
Clear all
NCT03899155
2026-06-03
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2
Recruiting
1,500 enrolled
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled
NCT01682083
2026-04-21
COMBI-AD
Novartis
Phase 3
Completed
870 enrolled
15 charts
1 FDA
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled